Le Lézard
Classified in: Covid-19 virus
Subjects: Conference, Webcast

Ares Capital Corporation to Present at the Barclays Virtual Global Financial Services Conference


Ares Capital Corporation ("Ares Capital") (NASDAQ:ARCC) announced today that Kipp deVeer, Ares Capital's Chief Executive Officer, is scheduled to present at the Barclays Virtual Global Financial Services Conference on Tuesday, September 14, 2021 at 11:15 am EDT.

A live audio webcast of the presentation will be available in the Investor Resources section of the Company's website at www.arescapitalcorp.com. For those unable to listen to the live audio webcast, a replay will be available on the Company's website through September 14, 2022.

ABOUT ARES CAPITAL CORPORATION

Founded in 2004, Ares Capital is a leading specialty finance company focused on providing direct loans and other investments in private middle market companies in the United States. Ares Capital's objective is to source and invest in high-quality borrowers that need capital to achieve their business goals, which often leads to economic growth and employment. Ares Capital believes its loans and other investments in these companies can generate attractive levels of current income and potential capital appreciation for investors. Ares Capital, through its investment manager, utilizes its extensive, direct origination capabilities and incumbent borrower relationships to source and underwrite predominantly senior secured loans but also subordinated debt and equity investments. Ares Capital has elected to be regulated as a business development company ("BDC") and is the largest BDC by market capitalization as of June 30, 2021. Ares Capital is externally managed by a subsidiary of Ares Management Corporation (NYSE: ARES), a publicly traded, leading global alternative investment manager.

FORWARD-LOOKING STATEMENTS

Statements included herein may constitute "forward-looking statements," which relate to future events or Ares Capital's future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties, including the impact of the COVID-19 pandemic and related changes in base interest rates and significant market volatility on Ares Capital's business, Ares Capital's portfolio companies, Ares Capital's industry and the global economy. Actual results and conditions may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Ares Capital's filings with the Securities and Exchange Commission. Ares Capital undertakes no duty to update any forward-looking statements made herein.


These press releases may also interest you

at 08:45
Reunion Gold Corporation (the "Company") is pleased to announce that it has signed a Mineral Agreement with the Cooperative Republic of Guyana and the Guyana Geology and Mines Commission. The Mineral Agreement provides the Company and its 100%-owned...

at 08:31
?     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through...

at 08:31
Sapiens International Corporation  , a leading global provider of software solutions for the insurance industry, today announced the launch of IntegrateAI, the newest capability from Sapiens Decision, integrating machine learning models into the...

at 08:30
Allison Transmission, a leading designer and manufacturer of conventional and electrified vehicle propulsion solutions for tactical wheeled and tracked defense vehicles, partnered with HST Otomotiv, Allison's licensed manufacturer in Türkiye, to...

at 08:30
Soligenix, Inc. ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering...

at 08:25
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA...



News published on and distributed by: